

SUSTAINABILITY DATA 2023

Social Data

ONO PHARMACEUTICAL CO., LTD.

Occurrence of occupational injuries

Item	Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Number of lost-time injuries	Non-consolidated (Employees)	Incidents	1	0	3	0	1
	Non-consolidated (Temporary employees) *2	Incidents	-	1	0	0	0
Lost-time injury frequency rate*1	Non-consolidated (Employees)	-	0.15	0	0.47	0	0.16
	Non-consolidated (Temporary employees) *2	-	-	2.09	0	0	0
Number of fatalities due to occupational accidents	Non-consolidated (Employees)	Persons	0	0	0	0	0
	Non-consolidated (Temporary employees) *2	Persons	-	0	0	0	0

*1 Lost-time injury frequency rate = (number of lost-time injuries / total number of actual working hours) x 1,000,000

*2 The data on the number of lost-time injuries and the lost-time injury frequency rate and the number of fatalities due to occupational accidents for temporary employees are subject to disclosure from FY2019.

Environmental Data

GHG emissions

Since the figures in the table are rounded, the breakdown totals may not always coincide with the overall totals.

Item	Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022	
GHG emissions scope breakdown (Market-basis) (a)	Scope 1 (Breakdown by GHG type)	Energy-derived	Non-consolidated	9.0	9.7	10.0	9.8	8.0
			Group Companies	-	-	-	-	0.0
		Non-energy-derived (HFCs, HCFCs)	Non-consolidated	0.5	0.4	0.1	0.03	0.2
			Group Companies	-	-	-	-	0.0
	Total		-	-	-	-	8.2	
	Scope 2	Non-consolidated	kt-CO ₂	19.1	17.1	15.9	13.7	10.2
		Group Companies		-	-	-	-	0.1
		Total		-	-	-	-	10.4
	Scope 1+2 (Total)	Non-consolidated	kt-CO ₂	28.5	27.3	26.1	23.6	18.4
		Group Companies		-	-	-	-	0.1
Total		-		-	-	-	18.6	
Amount of CO ₂ offset due to voluntary credit (Carbon-neutral city gas purchased)(b)	Non-consolidated	kt-CO ₂	-	-	-	0.6	0.7	
GHG emissions after offset (a-b)	Subtotal (Non-consolidated)	kt-CO ₂	-	-	-	23.0	17.7	
	Total		-	-	-	-	17.9	

Sites: [Non-consolidated] Fujiyama Plant, Joto Pharmaceutical Product Development Center, Yamaguchi Plant, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.

[Group companies] (FY2022-) ONO PHARMA USA, INC., Cambridge, ONO PHARMA UK LTD, London, ONO PHARMA KOREA CO., LTD, Seoul, ONO PHARMA TAIWAN CO., LTD, Taipei, and Ono Pharma UD Co., Ltd.

GHG emissions are calculated using the following formula.

[Domestic sites] GHG emissions = Purchased electricity × Adjusted emission factor published by electric power company + ∑ (Fuel consumption × Unit calorific value × Carbon emission factor × 44/12) + ∑ (Fluorocarbon leakage amount × Global warming potential)

[Overseas sites] Calculated by multiplying the amount of electricity purchased at overseas sites by the electric utility company's emission factor or the country-specific emission factor published by the IEA.

The amount of green electric power certified under the Green Energy Certificate and , the amount of renewable energy certified under the J-Credit Scheme and the Non-Fossil Fuel Certificate quota are deducted (Deducted CO₂ emissions: 3.2kt-CO₂) .

SUSTAINABILITY DATA 2023

GHG emissions in the supply chain (Scope3)

Since the figures in the table are rounded, the breakdown totals may not always coincide with the overall totals.

Category	Calculation method	Notes	Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
C1	Purchased goods and services	GHG emissions (scope 1.2) volume of our major suppliers of raw materials and materials (accounting for 80% or more of our raw materials or materials purchase costs) multiplied by the ratio of the sales to ONO out of the total sales of the supplier. Ratios for other business suppliers are assumed to follow the same trend as for major suppliers, and are calculated using the ratio of GHG emissions to the transaction amount at major suppliers.	Non-consolidated	kt-CO ₂	8.1	11.5	12.7	13.8	-
C2	Capital goods	Amount of capital goods treated as fixed assets (reinforcement of facilities/maintenance investment) excluding land, multiplied by factor		kt-CO ₂	60.4	26.9	25.8	26.4	21.3
C3	Fuel- and energy-related activities not included in scope 1 or scope 2	Amount of non-renewable electricity purchased, multiplied by emission factor		kt-CO ₂	1.5	2.8	2.7	2.4	2.1
C4	Upstream transportation and distribution	Transport data on deliveries from our production sites and distribution centers to destinations, multiplied by emission factor		kt-CO ₂	0.1	0.1	0.1	0.1	0.1
C5	Waste generated in operations	Weight of each type of industrial waste generated, multiplied by emission factor		kt-CO ₂	0.3	0.3	0.3	0.3	0.3
C6	Business travel	Business travel costs, multiplied by emission factor		kt-CO ₂	2.3	4.0	0.4	0.5	1.3
C7	Employee commuting	Commuting costs, multiplied by emission factor		kt-CO ₂	0.4	0.5	0.4	0.7	0.7
C8	Upstream leased assets	Fuel consumption used in leased vehicles, multiplied by emission factor		kt-CO ₂	3.3	2.9	2.0	2.1	1.9
C9	Downstream transportation and distribution	GHG emissions on our major pharmaceutical wholesalers, multiplied by percentage of our net sales included in all net sales of major pharmaceutical wholesalers		kt-CO ₂	5.3	4.9	5.0	5.5	-
C10	Processing of sold products	ONO makes only finished products		kt-CO ₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
C11	Use of sold products	No energy is consumed during the use of ONO products		kt-CO ₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
C12	End-of-life treatment of sold products	Weight of each type of our product container or packaging disposed of as waste, multiplied by emission factor		kt-CO ₂	0.2	0.2	0.2	0.1	0.2
C13	Downstream leased assets	Floor space of asset (building) owned and rented out categorized by use, multiplied by emission factor		kt-CO ₂	0.3	0.3	0.3	0.3	0.3
C14	Franchises	ONO does not operate franchises		kt-CO ₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
C15	Investments	There is no investment involving large amounts of greenhouse gas emissions.		kt-CO ₂	Not relevant	Not relevant	Not relevant	Not relevant	Not relevant
Total				kt-CO ₂	82.2	54.4	49.8	52.3	-

The emission factors used for calculation are figures stated in the "Emission Factor Database on Accounting for Greenhouse Gas Emissions throughout the Supply Chain (FY2018, Ver. 2.6; FY2019, Ver. 3.0; FY2020, Ver. 3.1; FY2021, Ver. 3.2; FY2022, Ver. 3.3)," published by the Ministry of the Environment, Government of Japan.
 Categories 1 and 9 and their total for FY2022 are not calculated because our major suppliers and pharmaceutical wholesalers had not published their GHG at the time of calculation.
 Only category 2 is consolidation.

SUSTAINABILITY DATA 2023

Energy consumption

Since the figures in the table are rounded, the breakdown totals may not always coincide with the overall totals.

Item	Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Energy consumption	Non-consolidated	MWh	93,763.8	101,605.6	103,204.3	99,499.9	86,067.6
	Group Companies		-	-	-	-	344.1
	Total		-	-	-	-	86,411.7

Sites: [Non-consolidated] Fujiyama Plant, Yamaguchi Plant, Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.

[Group companies] (FY2022-) ONO PHARMA USA, INC., Cambridge, ONO PHARMA UK LTD, London, ONO PHARMA KOREA CO., LTD, Seoul, ONO PHARMA TAIWAN CO., LTD, Taipei, and Ono Pharma UD Co., Ltd.

Electricity consumption and renewable energy usage rate

Since the figures in the table are rounded, the breakdown totals may not always coincide with the overall totals.

Item	Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022
Electricity consumption	Private power generation (renewable) (solar power generation)	Non-consolidated	65.0	63.0	63.3	61.9	64.4
		Group Companies	-	-	-	-	0.0
	Purchased electricity (renewable) (Non-fossil fuel)	Non-consolidated	-	1,278.0	1,954.7	2,040.0	3,480.0
		Group Companies	-	-	-	-	0.0
	Private power generation (non-renewable)	Non-consolidated	8,856.2	8,185.3	8,566.3	8,283.7	7,285.0
		Group Companies	-	-	-	-	0.0
	Purchased electricity (non-renewable)	Non-consolidated	43,734.4	46,351.7	45,232.2	42,833.5	37,821.6
		Group Companies	-	-	-	-	343.7
Subtotal (Non-consolidated total electricity consumption)			52,655.5	55,878.0	55,816.5	53,219.2	48,651.0
Total (total electricity consumption)			-	-	-	-	48,994.7
Amount of credits purchased	Solar power generation	Fujiyama Plant/Tsukuba Research Institute/Fukui Research Institute/Sales offices and other offices	-	2,427.0	4,946.6	3,937.9	0.0
	Biomass power generation		2,900.0	2,460.9	386.2	3,000.0	6,907.0
Renewable energy usage*	Total	MWh	2,965.0	6,228.9	7,350.7	9,039.9	10,451.4
Renewable energy usage rate (renewable energy usage / total electricity consumption)	Subtotal (Non-consolidated)	%	5.6	11.1	13.2	17.0	21.5
	Total		-	-	-	-	21.3

Sites: [Non-consolidated] Fujiyama Plant, Yamaguchi Plant, Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Head Office, sales offices and other offices, etc.

[Group companies] (FY2022-) ONO PHARMA USA, INC., Cambridge, ONO PHARMA UK LTD, London, ONO PHARMA KOREA CO., LTD, Seoul, ONO PHARMA TAIWAN CO., LTD, Taipei, and Ono Pharma UD Co., Ltd.

*Renewable energy usage = Private power generation (renewable) + Purchased electricity (renewable) + Amount of credits purchased

SUSTAINABILITY DATA 2023

Water intake and wastewater volume by site (unit: 1,000 m³)

Since the figures in the table are rounded, the breakdown totals may not always coincide with the overall totals.

Site name	River in the area	Wastewater drainage destination	FY2018		FY2019		FY2020		FY2021		FY2022	
			Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume	Water intake volume	Wastewater volume
Fujiyama Plant	Fuji River	River	240.2	178.4	185.0	145.1	157.8	125.0	138.7	110.2	122.9	100.1
Yamaguchi Plant	Fushino River	River	8.2	8.2	18.1	18.1	18.6	17.7	21.6	20.0	22.8	20.9
Joto Pharmaceutical Product Development Center	Yodo River	Sewer	6.0	6.0	5.1	5.1	4.6	4.6	3.9	3.9	3.4	3.4
Minase Research Institute	Yodo River	Sewer	41.2	41.2	39.1	39.1	33.7	33.7	31.5	31.5	32.2	32.2
Fukui Research Institute	Kuzuryu River	Sewer	31.3	5.0	27.3	5.7	13.7	2.6	6.6	1.9	0.8	0.2
Tsukuba Research Institute	Lake Kasumigaura	Sewer	6.0	6.0	7.1	7.1	7.2	7.2	7.0	7.0	4.7	4.7
Head Office and other sites in Japan (including tenant locations)	Rivers/lake in the areas around each business site*	Sewer	15.1	15.1	15.0	15.0	10.0	10.0	10.0	10.0	9.5	9.5
total			348.0	259.9	296.7	235.2	245.6	200.8	219.4	184.5	196.4	171.2

*Major basins: Toyohira River, Okura River, Arakawa River, Sakawa River, Kiso River, Lake Biwa, Yodo River, Ota River, Yoshino River, Naka River

Waste management

Since the figures in the table are rounded, the breakdown totals may not always coincide with the overall totals.

Item	Scope	Unit	FY2018	FY2019	FY2020	FY2021	FY2022	
Industrial waste	Waste generated	Non-consolidated	t	446.4	430.8	502.7	479.1	492.8
	【Waste breakdown】 Special management industrial waste (hazardous waste)*	Non-consolidated	t	145.6	161.9	171.2	170.3	142.5
	Final landfill disposal	Non-consolidated	t	0.4	0.2	1.1	0.2	0.1
	Final landfill disposal rate	Non-consolidated	%	0.1	0.1	0.2	0.04	0.02

Sites: Fujiyama Plant, Yamaguchi Plant, Joto Pharmaceutical Product Development Center, Minase Research Institute, Fukui Research Institute, Tsukuba Research Institute, Logistics centers (added from FY2021)

*Special management industrial waste (hazardous waste) is defined under the Waste Management and Public Cleansing Law as waste that has properties of explosiveness, toxicity, infectiousness, and/or possibly causing damage to human health or the living environment.

Independent Practitioner's Assurance Report

August 10, 2023

Mr. Gyo Sagara,
President, Representative Director, and CEO,
ONO PHARMACEUTICAL CO., LTD.

Tomoharu Hase
Representative Director
Deloitte Tohmatsu Sustainability Co., Ltd.
3-2-3, Marunouchi, Chiyoda-ku, Tokyo

We have undertaken a limited assurance engagement of the sustainability data indicated with for the year ended March 31, 2023 (the "Sustainability Data") included in the "SUSTAINABILITY DATA 2023 (PDF version)" (the "Report") of ONO PHARMACEUTICAL CO., LTD. (the "Company").

The Company's Responsibility

The Company is responsible for the preparation of the Sustainability Data in accordance with the calculation and reporting standard adopted by the Company (indicated with the Sustainability Data). Greenhouse gas quantification is subject to inherent uncertainty for reasons such as incomplete scientific knowledge used to determine emissions factors and numerical data needed to combine emissions of different gases.

Our Independence and Quality Control

We have complied with the independence and other ethical requirements of the Code of Ethics for Professional Accountants issued by the International Ethics Standards Board for Accountants, which is founded on fundamental principles of integrity, objectivity, professional competence and due care, confidentiality and professional behavior. We apply International Standard on Quality Control 1, *Quality Control for Firms that Perform Audits and Reviews of Financial Statements, and Other Assurance and Related Services Engagements*, and accordingly maintain a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards and applicable legal and regulatory requirements.

Our Responsibility

Our responsibility is to express a limited assurance conclusion on the Sustainability Data based on the procedures we have performed and the evidence we have obtained. We conducted our limited assurance engagement in accordance with the International Standard on Assurance Engagements ("ISAE") 3000, *Assurance Engagements Other than Audits or Reviews of Historical Financial Information*, issued by the International Auditing and Assurance Standards Board ("IAASB"), ISAE 3410, *Assurance Engagements on Greenhouse Gas Statements*, issued by the IAASB and the *Practical Guideline for the Assurance of Sustainability Information*, issued by the Japanese Association of Assurance Organizations for Sustainability Information.

The procedures we performed were based on our professional judgment and included inquiries, observation of processes performed, inspection of documents, analytical procedures, evaluating the appropriateness of quantification methods and reporting policies, and agreeing or reconciling with underlying records. These procedures also included the following:

- Evaluating whether the Company's methods for estimates are appropriate and had been consistently applied. However, our procedures did not include testing the data on which the estimates are based or reperforming the estimates.
- Undertaking site visits to assess the completeness of the data, data collection methods, source data and relevant assumptions applicable to the sites.

The procedures performed in a limited assurance engagement vary in nature and timing from, and are less in extent than for, a reasonable assurance engagement. Consequently, the level of assurance obtained in a limited assurance engagement is substantially lower than the assurance that would have been obtained had we performed a reasonable assurance engagement.

Limited Assurance Conclusion

Based on the procedures we have performed and the evidence we have obtained, nothing has come to our attention that causes us to believe that the Sustainability Data is not prepared, in all material respects, in accordance with the calculation and reporting standard adopted by the Company.

The above represents a translation, for convenience only, of the original Independent Practitioner's Assurance report issued in the Japanese language.